RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
Research has shown that anti-angiogenic agents can be effective therapies to treat cancer.
Anti-angiogenic agents target the blood vessels required for tumors to grow. Vascular
endothelial growth factor (VEGF) is one of the cell pathways used for this blood vessel
growth. When the investigators interfere with the VEGF pathway, the investigators inhibit
this blood vessel growth which is required by tumors. One of the study drugs being used,
tivozanib (AV-951), selectively interferes with the VEGF pathway. The second study drug being
used, everolimus (RAD001) interferes with the mTOR pathway. The mTOR pathway is another
pathway involved in blood vessel and tumor cell growth. By combining these two drugs the
investigators hope to slow or reverse tumor cell growth in patients whose tumors have become
resistant to other therapies for their disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
AVEO Pharmaceuticals, Inc. Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital Novartis